VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...

Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Sigma Planning Corp trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 8.7% during the third quarter, according to its most recent disclosure with the ...

Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

Vertex (VERX – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Chris Quintero from ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX). But which of these two stocks ...

These are the 300 companies whose success goes beyond profits to include employee and customer sentiment, cybersecurity, ...

Ken's career includes key leadership roles in organizations such as the Ontario Government, Victoria University (Toronto), Brock University, Cystic Fibrosis Canada, and Vertex Pharmaceuticals. His ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...